

Information Regarding Clinical Trial

Title	A Phase 1b Study of LY2835219 in Combination with Multiple Single-Agent Options for Patients with Stage IV NSCLC
Protocol Number	I3Y-MC-JPBJ
Sponsor	Lilly
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Open Part B , (Abemaciclib + Gemcitabine) at the 150mg Q12H assigned dose level in all sites in US and Spain. Part B: Patients who have received at least 1 but not more 3 prior therapies for advanced and/or metastatic NSCLC. LY +Alimta or Gem or Ramucirumab or Trametinimb